G01N 2800/7047
Fibrils-filaments-plaque formation
Official title: Fibrils-Filaments-Plaque formation
G01N2800/7047 (Fibrils-filaments-plaque formation) appears on 55 US grants and 87 published applications in this corpus.
Search patents in G01N- Granted patents
- 55
- Published applications
- 87
- Assignees
- 56
- Inventors
- 164
- Latest grant
- 10 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 1 | 4 |
| 2015 | 1 | 3 |
| 2016 | 3 | 8 |
| 2017 | 3 | 11 |
| 2018 | 3 | 7 |
| 2019 | 6 | 7 |
| 2020 | 6 | 12 |
| 2021 | 10 | 12 |
| 2022 | 10 | 5 |
| 2023 | 1 | 4 |
| 2024 | 7 | 2 |
| 2025 | 3 | 8 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for inhibiting intermediate filament tetramerization10 Mar 2026US 12,570,973 B2Yale University
- CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation23 Sep 2025US 12,421,512 B2Regeneron Pharmaceuticals, Inc.
- Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor25 Feb 2025US 12,234,281 B2Neurimmune Holding AG
- CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation28 Jan 2025US 12,209,238 B2Regeneron Pharmaceuticals, Inc.
- Assay for the detection of alpha-synuclein seeding activity associated with synucleinopathies1 Oct 2024US 12,105,101 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Compositions and Methods for Inhibiting Intermediate Filament Tetramerization13 Aug 2026US 2026/0234612 A1Yale University
- Crispr/cas screening platform to identify genetic modifiers of tau seeding or aggregation19 Feb 2026US 2026/0049305 A1Regeneron Pharmaceuticals, Inc.
- Anti-transthyretin (ttr) binding proteins and uses thereof22 May 2025US 2025/0163136 A1
- Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor15 May 2025US 2025/0154235 A1Neurimmune Holding AG
- Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor8 May 2025US 2025/0145699 A1Neurimmune Holding AG
Most cited
By later US patents
- Antibodies to TTR and methods of use13US 9,534,048 B2University Health Network · 2017
- Anti-PHF-tau antibodies and uses thereof9US 10,766,953 B2Janssen Biotech, Inc. · 2020
- Anti-transthyretin antibodies8US 10,633,433 B2Prothena Biosciences Limited · 2020
- Bacteriophage gene 3 protein compositions and use as amyloid binding agents7US 9,493,515 B2Proclara Biosciences, Inc. · 2016
- Bacteriophage gene 3 protein compositions and use as amyloid binding agents5US 9,493,516 B2Proclara Biosciences, Inc. · 2016